Structure-based Discovery of Di(indole)methylarylcarboxylate Compounds as Retinoid X Receptor Agonists and Their Activity against Prostate Cancer Cells
Written by Mao Ye   
Thursday, 18 June 2009 03:42

Structure-based Discovery of Di(indole)methylarylcarboxylateCompounds as Retinoid X Receptor Agonists and Their Activity against Prostate Cancer Cells

Abstract:Di(indole)methylarylcarboxylates(DIM-arenes) were designed and synthesized. Competitive binding using labeled 9-cis-retinoic acid showed that DIM-Ph-CF3(BI-1043) bound to the RXRαligand-binding domain (LBD) with an IC50= 14 μM. Replacing the CF3 group by a CO2H group produced DIM-Ph-CO2H (BI-1044) with an IC50= 6 μM. These results and those in transcriptional activation reporter assays suggested that substituted DIM-arenescould function through RXR in exerting their growth inhibitory effects on prostate cancer cells. Computational studies were used to guide structural modifications of the aryl ring to improve binding affinity to RXR in the effort to improve prostate cancer cell growth inhibition. Identification of a more potent RXR ligandmay enhance the efficacy of current prostate cancer therapeutic agents, thereby permitting use at lower doses to reduce adverse systemic effects.

Mao Ye1,Qiong-Ying Hu1,Xi-Hua Hu1,Xiao-Kun Zhang1,Marcia Dawson1

1Cancer Center, Burnham Institute for Medical Research

Keywords: structure-based drug design , prostate cancer , retinoid X receptor (RXR) , synthesis


Only registered users can write comments!

3.26 Copyright (C) 2008 / Copyright (C) 2007 Alain Georgette / Copyright (C) 2006 Frantisek Hliva. All rights reserved."